Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

BACKGROUND: Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively review...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng
Format: Artigo
Language:Inglês
Published: BioMed Central 2021
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8314552/
https://ncbi.nlm.nih.gov/pubmed/34315431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08587-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items